The development of GMP-grade stable cell lines is a critical step in advancing biologics from preclinical research to clinical trials and commercial manufacturing. It requires not only high expression and stability, but also strict compliance with regulatory standards, traceability, and comprehensive documentation.
Profacgen offers GMP-grade stable cell line development services supported by an efficient, rapid, and robust expression platform. Our integrated approach significantly improves protein expression levels, reduces development timelines by up to 50%, and ensures full compatibility with global regulatory requirements. With capabilities including serum-free suspension culture, label-free expression systems, and complete cell banking services, we provide high-quality, flexible solutions to support IND-enabling studies and large-scale GMP production.
Profacgen has established an efficient, rapid, and stable expression system for recombinant protein production suitable for GMP-compliant manufacturing. As biologics development progresses toward clinical and commercial stages, regulatory authorities require that production cell lines meet stringent standards in terms of:
Stable cell lines intended for GMP production must exhibit the following characteristics:
At Profacgen, the source of host cells is clearly defined and free from intellectual property concerns, ensuring regulatory confidence and freedom to operate.
However, achieving these standards requires more than traditional cell line development. It demands a GMP-oriented workflow, integrating:
Profacgen provides a comprehensive, end-to-end GMP-grade cell line development solution, covering all stages from vector construction to validated cell banking.
Expression Vector Construction and Cell Line Generation
According to customer requirements, we begin with expression vector design and construction, followed by transfection into host cells to generate high-expression cell pools.
Capabilities:
Advanced Features:
We generate high-expression stable pools as the foundation for downstream clone screening and development.
Clone Screening and Monoclonality Assurance
After transfection, we perform rigorous screening and analysis to identify high-expression clones.
Core Workflow:
Enhanced Capabilities:
These approaches ensure high success rates in identifying high-producing, stable, and regulatory-compliant clones.
Cell Banking: MCB and WCB Establishment
We provide full cell banking services compliant with GMP expectations.
Procedure:
Additional Features:
Characterization and Stability Studies
We perform comprehensive characterization and stability testing to ensure cell line reliability.
Testing Scope:
Biosafety and Compliance Studies:
These studies cover the entire production lifecycle, ensuring readiness for regulatory submission.
Product Quality Analysis
Product quality is a central focus during GMP cell line development.
Key Analyses:
This ensures that the produced biologics meet both functional requirements and regulatory standards.
Process Development and GMP Readiness
Our development strategy is aligned with downstream manufacturing and regulatory expectations.
Capabilities:
We provide flexible and high-quality services to meet global GMP production requirements and support regulatory submissions.
Challenge:
A biotech company required a GMP-grade CHO cell line for monoclonal antibody production to support an IND submission within an aggressive timeline. Any delays would impact their clinical development milestones.
Approach:
Profacgen initiated rapid vector construction and transfection to accelerate the workflow. Double resistance screening enabled efficient selection of high-producer clones. Parallel establishment of master cell banks (MCB) and working cell banks was conducted to streamline GMP documentation and release testing.
Outcome:
Delivered a GMP-compliant MCB within the required timeline, fully documented and tested for safety and stability. The cell line achieved high yield exceeding 6 g/L in fed-batch production. The client successfully utilized the MCB for IND submission, meeting all regulatory requirements and advancing to clinical trials.
Challenge:
A client preparing for commercial manufacturing required a cell line capable of maintaining long-term stability and consistent product quality throughout the full production cycle.
Approach:
Profacgen conducted extended stability testing across multiple passages to evaluate productivity and genetic integrity. Gene expression analysis using qPCR and sequencing was performed to monitor transgene retention. Product quality attributes including glycosylation profiles, aggregation, and charge variants were carefully tracked.
Outcome:
The selected cell line demonstrated stable expression across the full production cycle with no productivity decline. Glycosylation profiles remained consistent across passages, ensuring reproducible product quality. Successful scale-up to commercial production was achieved, meeting the client's regulatory requirements and market supply goals.
Challenge:
A client needed to develop a GMP cell line for a highly glycosylated protein with strict quality control requirements. Regulatory expectations demanded rigorous characterization and consistency.
Approach:
Profacgen adapted the cell line to serum-free suspension culture to align with GMP manufacturing standards. Process optimization including fed-batch and perfusion strategies was implemented to maximize yield while maintaining product quality. Detailed characterization studies encompassing glycosylation, purity, and stability were conducted.
Outcome:
Achieved regulatory-compliant product quality with well-defined critical quality attributes. Batch consistency was significantly improved, meeting specifications across multiple runs. The client successfully progressed into clinical trials with the approved cell line and manufacturing process.
Consult Our Experts on Your Project
Fill out this form and one of our experts will respond to you within one business day.